Home
Search

Press Releases

Get the latest on BIO’s announcements, positions, and views.

Featured Press Releases
U.S. Bioscience Industry Powers Over $3 Trillion…
WASHINGTON, DC (October 28, 2026) – Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact…
Learn more
BIO Statement on Proposed Rule to Implement…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the proposed Outbound Investment Security Program (OISP) rule:"The Administration is correct that…
Learn more
BIO Statement on the FDA’s ‘Fit-for-Purpose Rare…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the FDA’s ‘Fit-for-Purpose Rare Disease Framework Initiative.’“Today’s announcement is an important step…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
CMS’ Attempt to Restrict Patient Access to Alzheimer’s Drug Sets “Dangerous and Far-Reaching” Precedent
January 13, 2022
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) proposed National Coverage Determination (NCD) to…
"Build Back Better Act" Drug Pricing Provisions Weaken U.S. Innovation Ecosystem, Hurt Patients
November 19, 2021
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement after the House of Representatives passed the Build Back Better Act: “The legislation that passed the House today…
Patients Empowered with New “Clinical Trials: The Power of Participation” Website
November 16, 2021
The Biotechnology Innovation Organization (BIO) today announced the launch of Clinical Trials: The Power of Participation (CTPoP), a website that addresses how clinical trials work, how to enroll in a clinical trial, and what to expect as a clinical…
White House’s “Build Back Better” Plan Builds New Barriers for Patients and Scientists Discovering Groundbreaking Cures
November 4, 2021
Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), made the following statement: "Last week, Democratic leaders announced they had reached a drug pricing “deal.” We wanted to see the details before…
Proposed Prescription Drug User Fee Act VII Performance Goals Letter Earns BIO Support
August 24, 2021
Biotechnology Innovation Organization (BIO) Chief Scientific Officer, E. Cartier Esham issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VII performance goals letter:“The Prescription Drug User Fee Act …
Biden Drug Plan Adds Barriers to Seniors Accessing Lifesaving Medicines
August 12, 2021
President Joe Biden today announced a slew of drug pricing reforms, including changes that would radically alter the widely successful Medicare program for seniors and people with disabilities. Rich Masters, BIO’s Chief Public Affairs and Advocacy…
BIO Announces 2021 Start-up Stadium Winner: Kayothera Inc.
July 27, 2021
Annual competition takes place during BIO’s International Convention
BIO Promotes Sarah Gallo to Vice President, Agriculture and Environment
July 22, 2021
The Biotechnology Innovation Organization (BIO) is pleased to announce today the promotion of Sarah Gallo to Vice President, Agriculture and Environment. In her new role, Sarah will lead the policy and market access strategies for BIO’s Agriculture…
BIO Cheers Senate Passage of Growing Climate Solutions Act
June 24, 2021
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement after the Senate passed the Growing Climate Solutions Act: “This bill is at the heart of everything we fight…
BIO Releases Second Annual DEI Report
June 17, 2021
Diversity, Equity and Inclusion a Priority in Majority of Biotech Organizations